AndroGel Is Not Injected: Proper Topical Application Technique for Testosterone Gel

Why "AndroGel Self-Injection" Is a Misnomer

AndroGel is a hydroalcoholic topical gel. It contains no needle, no syringe, and no intramuscular or subcutaneous delivery component. The phrase "AndroGel self-injection technique" likely stems from search confusion between testosterone gel and injectable testosterone formulations such as testosterone cypionate or testosterone enanthate, which do require self-injection.

The FDA-approved prescribing information for AndroGel classifies the product as a topical gel for external use only. The 1% formulation (marketed as AndroGel 1%) delivers testosterone through metered-dose pumps or unit-dose packets. The 1.62% formulation uses pump actuation to dispense 20.25 mg of testosterone per press. Both formulations rely on transdermal absorption, a mechanism that is pharmacologically distinct from intramuscular injection [1].

Patients prescribed AndroGel should never attempt to inject the gel formulation. The excipients (ethanol, carbomer, purified water) are designed for epidermal penetration, not parenteral administration. If a clinician has recommended injectable testosterone, the correct product is testosterone cypionate (Depo-Testosterone) or testosterone enanthate, each with its own needle gauge, injection site, and self-administration protocol.

How AndroGel Works: Transdermal Testosterone Delivery

Testosterone gel uses the skin as a drug reservoir. After application, ethanol in the gel vehicle evaporates and deposits testosterone into the stratum corneum. From there, testosterone diffuses through the epidermis and dermis into dermal capillaries, entering systemic circulation.

Bioavailability sits around 10%. That means for every 50 mg of testosterone applied to the skin, roughly 5 mg reaches the bloodstream [1]. This is lower than intramuscular injection (which approaches 100% bioavailability), but the trade-off is pharmacokinetic stability. Injections of testosterone cypionate produce a peak within 24 to 48 hours followed by a trough over 7 to 14 days. Topical gel, applied daily, produces relatively flat serum testosterone concentrations once steady state is reached.

The Testosterone Trials (TTrials), a coordinated set of seven placebo-controlled trials enrolling 790 men aged 65 and older with serum testosterone below 275 ng/dL, demonstrated that daily application of testosterone gel (AndroGel 1%) raised serum testosterone into the normal range (300 to 1 to 000 ng/dL) and maintained it over 12 months. Participants in the testosterone arm showed improvements in sexual function, walking distance, and mood compared to placebo [2].

A pharmacokinetic study published in the Journal of Clinical Endocrinology & Metabolism found that AndroGel 1.62% at the 40.5 mg dose achieved mean steady-state testosterone (C_avg) of 495 ng/dL, with 82% of subjects maintaining levels within the eugonadal range throughout the dosing interval [3].

Step-by-Step Application Technique

Proper technique affects absorption, consistency of serum levels, and safety for household contacts. The following steps reflect the manufacturer's prescribing information and published pharmacokinetic data.

Step 1: Wash and dry hands. Residual soap or lotion can alter gel absorption. Dry skin improves ethanol evaporation.

Step 2: Dispense the prescribed dose. For AndroGel 1.62%, one pump actuation delivers 20.25 mg. A starting dose is typically 40.5 mg (two actuations). For AndroGel 1%, packets contain 25 mg or 50 mg. Do not estimate. Use the exact number of actuations or packets prescribed.

Step 3: Apply to the correct anatomical site. For the 1.62% formulation, apply to the front and inner sides of the upper arms and shoulders only. For the 1% formulation, apply to the abdomen or upper arms. Do not apply to the chest, genitals, or any area with broken skin.

Step 4: Spread the gel thinly and evenly. Do not rub vigorously. A thin, even layer maximizes surface area for absorption without pooling.

Step 5: Allow the site to dry completely before dressing. The prescribing information recommends waiting at least 2 hours before swimming, showering, or putting on clothing that will cover the application site. Early washing reduces absorption. A crossover study in 24 hypogonadal men found that showering 1 hour after application reduced testosterone AUC by 12.7%, while waiting 6 hours had negligible effect [4].

Step 6: Wash hands thoroughly with soap and water. This step is non-negotiable. Residual testosterone on the hands can transfer to objects, other people, or mucous membranes.

Step 7: Cover the application site with clothing once dry. This reduces the risk of secondary transfer through skin-to-skin contact.

Dose Titration and Monitoring

Starting dose for most men is 40.5 mg daily (AndroGel 1.62%) or 50 mg daily (AndroGel 1%). The prescribing information directs clinicians to check serum testosterone 14 days after initiation and at least 14 days after any dose adjustment.

Blood should be drawn 2 to 8 hours after gel application on the morning of the lab visit. This timing captures the approximate C_max window. The target: total testosterone between 300 and 1 to 000 ng/dL per the Endocrine Society's 2018 Clinical Practice Guideline for testosterone therapy in men with hypogonadism [5].

If levels fall below 300 ng/dL, the dose may be increased by 20.25 mg increments (1.62% formulation) up to a maximum of 81 mg daily. If levels exceed 750 ng/dL, the dose should be decreased. The Endocrine Society guideline states: "Clinicians should aim for the mid-normal range and adjust based on symptom response and serum levels" [5].

Hematocrit must be checked at baseline, 3 months, 6 months, and annually. Testosterone therapy increases erythropoiesis. If hematocrit exceeds 54%, the Endocrine Society recommends stopping therapy, evaluating for hypoxia or sleep apnea, and restarting at a lower dose once hematocrit normalizes [5]. A retrospective cohort analysis of 3,422 men on testosterone therapy found that 6.4% developed polycythemia (hematocrit above 52%) within the first year, with higher rates among men receiving injections compared to gel [6].

Transfer Risk: The Unique Safety Concern of Topical Testosterone

Injectable testosterone carries no transfer risk. Topical formulations do. The FDA added a black box warning to all testosterone gel products in 2009 after post-marketing reports of virilization in children who had skin-to-skin contact with adult men using these products [7].

Reported cases included a 2-year-old girl who developed pubic hair and clitoral enlargement after regular contact with her father's bare shoulders. Serum testosterone in affected children reached levels 50 to 100 times the normal prepubertal range [7].

Prevention requires three actions after every application. First, wash hands with soap and water. Second, cover the application site with clothing once dry. Third, if skin-to-skin contact with another person occurs before the site is washed or covered, that person should wash the contact area immediately with soap and water.

Women who are pregnant or may become pregnant should avoid all contact with testosterone gel application sites. Testosterone is classified as FDA Pregnancy Category X, meaning it can cause virilization of a female fetus [1].

AndroGel vs. Injectable Testosterone: When Gel Is the Right Choice

The choice between topical and injectable testosterone depends on pharmacokinetic preference, needle comfort, cost, and clinical scenario. Neither is universally superior.

Gel produces stable daily testosterone levels. A study in Clinical Endocrinology comparing testosterone gel to biweekly testosterone enanthate 250 mg intramuscular injections found that gel users had a testosterone coefficient of variation (CV) of 15%, while injection users had a CV of 52% over each dosing interval [8]. Stable levels may matter for mood, energy, and libido in men sensitive to hormonal fluctuation.

Injections cost less. Generic testosterone cypionate 200 mg/mL costs approximately $30 to $50 for a 10 mL vial (roughly a 10-week supply at 100 mg per week). AndroGel 1.62% without insurance runs $500 to $700 per month, though manufacturer coupons and generic alternatives (Teva's authorized generic) reduce this to $50 to $150 for some patients.

The Endocrine Society guideline does not recommend one formulation over another, stating: "The choice of testosterone formulation is a shared decision based on patient preference, pharmacokinetics, cost, and formulation-specific adverse effects" [5]. Gel is often preferred for men who want to avoid needles, need steady-state pharmacokinetics, or have a history of injection-site reactions.

Men who share a household with children or pregnant women should weigh transfer risk carefully. In these scenarios, injectable testosterone or testosterone patches (which have a lower transfer risk due to adhesive backing) may be safer choices [7].

Common Application Errors That Reduce Absorption

Three mistakes account for most cases of subtherapeutic testosterone levels in gel users.

Applying to the wrong site. AndroGel 1.62% is validated for absorption on the upper arms and shoulders. Applying it to the abdomen, thighs, or back may change absorption kinetics. The 1% formulation, by contrast, was studied with abdominal application. Using the wrong product on the wrong site can reduce bioavailability by an unknown margin.

Showering too soon. Washing the application site within 2 hours removes unabsorbed testosterone. As noted above, even a 1-hour delay after application reduces AUC by over 12% [4]. Morning applicators who shower before work should apply gel after their shower, not before.

Using sunscreen or lotion on the application site. A pharmacokinetic interaction study found that applying sunscreen (SPF 30) to the same area 30 minutes before testosterone gel reduced testosterone absorption by approximately 14% [9]. Emollients, moisturizers, and other topical products should be kept off application sites.

Switching From Gel to Injections (or Vice Versa)

Switching between formulations requires coordination. There is no direct milligram-to-milligram equivalence between topical and injectable testosterone because bioavailability differs so widely (10% for gel vs. close to 100% for intramuscular).

General guidance from the American Urological Association recommends measuring trough testosterone 2 weeks after switching to confirm adequate levels [10]. A man on AndroGel 1.62% at 40.5 mg/day (delivering roughly 4 mg of bioavailable testosterone) might start injectable testosterone cypionate at 50 to 80 mg per week, then titrate based on labs. The reverse switch (injections to gel) should begin the day after the last injection was due, using mid-range gel dosing.

No washout period is necessary. Testosterone gel has a half-life in the skin reservoir of approximately 12 hours. Serum levels decline within 24 to 48 hours of discontinuation [1].

Storing and Handling AndroGel

Store at 20 to 25 degrees Celsius (68 to 77 degrees Fahrenheit). Keep out of reach of children. The gel is flammable due to its alcohol content. Do not apply near open flame and allow complete drying before smoking or approaching ignition sources. Pumps should be primed with three actuations before first use (discard priming doses onto a paper towel and dispose of in household trash).

Unused packets or expired product should not be flushed. The FDA recommends disposal through a drug take-back program or, if unavailable, mixing with an undesirable substance (coffee grounds, cat litter) in a sealed container before placing in household trash [7].